Novel inhibitors of the egfr kinase targeting the asymmetric activating dimer interface

作者: Xuewu Zhang , Philip Cole , John Kuriyan

DOI:

关键词:

摘要: The invention provides methods and compositions for the modulation of EGFR activity, in particular, inhibition activation through an allosteric mechanism is discloses, as a method targeted drug discovery design based on models three dimensional structure kinase domains protein dimers.

参考文章(35)
Alan R. Soltiel, Ellen M. Dobrusin, Andrea Thieme-Sefler, Dennis J. Mcnamara, Derek Maclean, Peptide antagonists of sh2 binding and therapeutic uses thereof ,(1993)
Zakaria Rachid, Bertrand Jean-Claude, Fouad Brahimi, Novel combi-molecules having EGFR and DNA targeting properties ,(2005)
Matthias H. Kraus, C. Richter King, Stuart A. Aaronson, erbB-2 gene segments, probes, recombinant DNA and kits for detection ,(1995)
Lewis C. Cantley, Zhou Songyang, Substrate specificity of protein kinases ,(1995)
L. Michael Furness, Jenny L. Buchbinder, Genes expressed in C3A liver cell cultures treated with steroids ,(2001)
Chung-leung Chan, Gordon N. Gill, Mutational Analysis of the Nucleotide Binding Site of the Epidermal Growth Factor Receptor and v-Src Protein-tyrosine Kinases Journal of Biological Chemistry. ,vol. 271, pp. 22619- 22623 ,(1996) , 10.1074/JBC.271.37.22619
Liao Jeffrey, Andrews Robert, Targeting protein multiple conformations: a structure-based strategy for kinase drug design. Current Topics in Medicinal Chemistry. ,vol. 7, pp. 1394- 1407 ,(2007) , 10.2174/156802607781696783
Janet Dancey, Edward A. Sausville, Issues and progress with protein kinase inhibitors for cancer treatment. Nature Reviews Drug Discovery. ,vol. 2, pp. 296- 313 ,(2003) , 10.1038/NRD1066